The Claim
In patients with non-obstructive coronary artery disease, statin use is not associated with differences in low-attenuation plaque burden, indicating that statins do not reduce the most vulnerable plaque subtype.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with non-obstructive coronary artery disease, taking statins does not change the amount of low-attenuation plaque in the arteries, which is the type of plaque most likely to cause heart attacks.
See the scientific wording
In patients with non-obstructive coronary artery disease, statin use is not associated with differences in low-attenuation plaque burden, suggesting statins do not reduce the most vulnerable plaque subtype.
Statins lower cholesterol in the blood, which reduces the amount of fat inside artery plaques. This causes the plaque to become less fatty and more calcified, making it harder and more stable, but it does not shrink the dangerous soft core that can rupture and cause heart attacks.
What the research says
1 studyThis study found that statins don’t reduce the soft, fatty plaques that are most likely to cause heart attacks, even though they do make plaques more calcified and stable. So yes, statins don’t seem to shrink the most dangerous type of plaque in these patients.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.